Caroline Caramella
Overview
Explore the profile of Caroline Caramella including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
85
Citations
3531
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Issard J, Brioude G, Mitilian D, Fabre D, de Montpreville V, Hanna A, et al.
Surg Oncol
. 2024 Jul;
56:102100.
PMID: 39024682
Objectives: Lower bilobectomy (LBL) leaves a residual pleural space potentially associated with adverse postoperative outcomes. In selected patients, right sleeve lower lobectomy (RSLL) with anastomosis between the middle lobe bronchus...
2.
Djahnine A, Lazarus C, Lederlin M, Mule S, Wiemker R, Si-Mohamed S, et al.
Diagn Interv Imaging
. 2024 Jan;
105(3):97-103.
PMID: 38261553
Purpose: The purpose of this study was to propose a deep learning-based approach to detect pulmonary embolism and quantify its severity using the Qanadli score and the right-to-left ventricle diameter...
3.
Malka D, Verret B, Faron M, Guimbaud R, Caramella C, Edeline J, et al.
Eur J Cancer
. 2023 Nov;
195:113400.
PMID: 37922632
Background: The efficacy and tolerability of hepatic arterial infusion (HAI) oxaliplatin plus systemic 5-fluorouracil and cetuximab as frontline treatment in patients with colorectal liver metastases (CRLM) are unknown. Methods: In...
4.
Pasquier D, Bidaut L, Oprea-Lager D, deSouza N, Krug D, Collette L, et al.
Lancet Oncol
. 2023 Aug;
24(8):e331-e343.
PMID: 37541279
Breast cancer remains the most common cause of cancer death among women. Despite its considerable histological and molecular heterogeneity, those characteristics are not distinguished in most definitions of oligometastatic disease...
5.
Belkouchi Y, Lederlin M, Afia A, Fabre C, Ferretti G, de Margerie C, et al.
Diagn Interv Imaging
. 2023 Jun;
104(10):485-489.
PMID: 37321875
Purpose: In 2022, the French Society of Radiology together with the French Society of Thoracic Imaging and CentraleSupelec organized their 13th data challenge. The aim was to aid in the...
6.
Pradere P, Caramella C, Salem F, Florea V, Crutu A, Hanna A, et al.
Clin Lung Cancer
. 2023 Apr;
24(5):453-458.
PMID: 37030992
Introduction: Despite the increasing importance of digital resources in modern life over the past decades, little is known about the impact of internet-based solutions on patient's health. We aimed to...
7.
Boulate D, Fidelle M, Caramella C, Issard J, Planche O, Pradere P, et al.
BMJ Open
. 2022 Dec;
12(12):e067191.
PMID: 36572501
Introduction: Eligibility criteria definition for a lung cancer screening (LCS) is an unmet need. We hypothesised that patients with a history of atheromatous cardiovascular disease (ACVD) associated with tobacco consumption...
8.
Unterrainer M, Deroose C, Herrmann K, Moehler M, Blomqvist L, Cannella R, et al.
Eur J Cancer
. 2022 Oct;
176:193-206.
PMID: 36274570
Background: Treatment monitoring in metastatic colorectal cancer (mCRC) relies on imaging to evaluate the tumour burden. Response Evaluation Criteria in Solid Tumors provide a framework on reporting and interpretation of...
9.
deSouza N, van der Lugt A, Deroose C, Alberich-Bayarri A, Bidaut L, Fournier L, et al.
Insights Imaging
. 2022 Oct;
13(1):159.
PMID: 36194301
Background: Lesion/tissue segmentation on digital medical images enables biomarker extraction, image-guided therapy delivery, treatment response measurement, and training/validation for developing artificial intelligence algorithms and workflows. To ensure data reproducibility, criteria...
10.
Sedlaczek O, Kleesiek J, Gallagher F, Murray J, Prinz S, Perez-Lopez R, et al.
Eur Radiol
. 2022 Jun;
32(12):8617-8628.
PMID: 35678860
Objectives: In the Cancer Core Europe Consortium (CCE), standardized biomarkers are required for therapy monitoring oncologic multicenter clinical trials. Multiparametric functional MRI and particularly diffusion-weighted MRI offer evident advantages for...